• If you are wondering whether ICON's current share price reflects its underlying value, the recent moves in the stock give you a timely reason to take a closer look.
• The stock recently closed at US$121.32, with returns of 18.4% over 7 days and 6.2% over 30 days, set against a year-to-date return of a 35.7% decline and a 10.2% decline over the past year.
• These price moves have come as ICON continues to attract attention in the contract research and life sciences outsourcing space, where investors often focus on the resilience and visibility of long-term client relationships. This backdrop can help you frame whether recent share price swings align with your own expectations for risk and potential reward.
• ICON currently has a valuation score of 5/6, which means it screens as undervalued on most of the checks used in this framework. The next sections will walk through the main valuation approaches used here and then finish with a different way of thinking about value that can round out your view.

Approach 1: ICON Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today using a required return, to estimate what the business could be worth right now.

For ICON, the model used is a 2 Stage Free Cash Flow to Equity approach, based on last twelve months free cash flow of about $980.9 million. Analyst forecasts are available for several years, with Simply Wall St extrapolating further out to a projected free cash flow of $979.55 million in 2030 and extending estimates through 2035. All cash flows here are in $.

Bringing these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $188.74 per share. Compared with the recent share price of $121.32, this implies the stock is 35.7% undervalued according to this framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ICON is undervalued by 35.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: ICON Price vs Earnings

P/E is a useful way to think about valuation for profitable companies because it directly links what you pay for the stock to the earnings it currently generates. A higher P/E is often associated with stronger expected growth or lower perceived risk, while a lower P/E can reflect more modest expectations or higher uncertainty.

ICON currently trades on a P/E of 15.45x. That sits below the Life Sciences industry average P/E of 36.53x and the peer group average of 52.43x, so the stock is priced at a lower multiple of earnings than many companies in its space. On its own, though, that gap does not tell you whether the stock is attractively priced, because peers can have very different growth profiles and risk levels.

Simply Wall St’s Fair Ratio framework estimates what a reasonable P/E might be for ICON at 17.16x, based on factors such as earnings growth, profit margins, industry, market cap and risk. This tailored view can be more informative than a simple comparison with peers or the broad industry, because it adjusts for the company’s own characteristics rather than assuming all stocks deserve similar multiples. Set against the current 15.45x P/E, the Fair Ratio suggests ICON screens as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your ICON Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in. They give you a simple way to attach a clear story about ICON to hard numbers like your fair value, and your own estimates for future revenue, earnings and margins.

On Simply Wall St’s Community page, Narratives let you connect what you believe about ICON’s business, such as the impact of oncology expansion, AI tools like iSubmit and SmartDraft, or accounting and backlog risk, to a full forecast and then to a fair value that you can set against today’s share price to decide whether the stock looks above or below what you think it is worth.

Because Narratives update when new earnings, news or analyst targets arrive, you can see how a more optimistic view, such as a fair value around US$226.60 that assumes revenue growth of 3.2% a year and higher margins, compares with a cautious view closer to US$75.00 that assumes flat revenue and lower margins, then decide which story you currently find more reasonable for ICON.

For ICON however we will make it really easy for you with previews of two leading ICON Narratives:

Fair value in this bullish narrative: US$132.08 per share.

Implied discount to this fair value at US$121.32: about 8.1% undervalued.

Analyst modeled revenue growth used in this view: 2.0% a year.

• Focuses on oncology and midsized pharma partnerships, with site and lab expansion as key revenue drivers.
• Builds on AI tools like iSubmit and SmartDraft, along with operational standardisation, to support higher margins and earnings.
• Relies on continued share repurchases and a strong balance sheet to support earnings per share, while accepting trial cancellations and competition as key risks.

Fair value in this bearish narrative: US$75.00 per share.

Implied downside to this fair value at US$121.32: about 61.1% overvalued.

Analyst modeled revenue growth used in this view: 0.6% a year.

• Emphasises elevated trial cancellations, pricing pressure and intense competition as headwinds for growth and margins.
• Flags regulatory complexity, deglobalisation and potential client concentration as constraints on international expansion.
• Assumes earnings and margins compress from today’s levels, with a lower future P/E multiple reflecting accounting review and backlog uncertainty.

Both narratives use the same raw data but tell very different stories about ICON. The key step for you is deciding which set of assumptions feels closer to how you see the business and its risks today, then anchoring your own fair value around that view instead of the latest share price moves.

Do you think there's more to the story for ICON? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.